Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation.

Autor:	Qian F; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Tintle N; Department of Mathematics and Statistics, Dordt University, Sioux Center, Iowa, USA; Fatty Acid Research Institute, Sioux Falls, South Dakota, USA., Jensen PN; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA., Lemaitre RN; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA., Imamura F; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom., Feldreich TR; School of Health and Social Sciences, Dalarna University, Falun, Sweden; Center for Clinical Research Dalarna, Region Dalarna, Falun, Sweden., Nomura SO; Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA., Guan W; Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA., Laguzzi F; Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Kim E; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Virtanen JK; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland., Steur M; Department of Epidemiology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands., Bork CS; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark., Hirakawa Y; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., O'Donoghue ML; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Sala-Vila A; Fatty Acid Research Institute, Sioux Falls, South Dakota, USA; Cardiovascular Risk and Nutrition - Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain., Ardisson Korat AV; Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA., Sun Q; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Rimm EB; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Psaty BM; Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Systems and Population Health, University of Washington, Seattle, Washington, USA., Heckbert SR; Cardiovascular Health Research Unit, Department of Epidemiology, University of Washington, Seattle, Washington, USA., Forouhi NG; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom., Wareham NJ; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom., Marklund M; Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden; Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA; The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia., Risérus U; Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden., Lind L; Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Ärnlöv J; Center for Clinical Research Dalarna, Region Dalarna, Falun, Sweden; School of Health and Social Studies, Dalarna University, Falun, Sweden; Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Stockholm, Sweden., Garg P; Division of Cardiology, University of Southern California Keck School of Medicine, Los Angeles, California, USA., Tsai MY; Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA., Pankow J; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA., Misialek JR; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA., Gigante B; Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Leander K; Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Pester JA; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Albert CM; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Kavousi M; Department of Epidemiology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands., Ikram A; Department of Epidemiology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands., Voortman T; Department of Epidemiology, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands; Division of Human Nutrition and Health, Wageningen University and Research, Wageningenn, the Netherlands., Schmidt EB; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Ninomiya T; Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Morrow DA; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Bayés-Genís A; Department of Cardiology, Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain., O'Keefe JH; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA., Ong KL; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Wu JHY; The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia., Mozaffarian D; Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA; Division of Cardiology, Tufts Medical Center, Boston, Massachusetts, USA., Harris WS; Fatty Acid Research Institute, Sioux Falls, South Dakota, USA; Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota, USA., Siscovick DS; The New York Academy of Medicine, New York, New York, USA. Electronic address: dsiscovick@nyam.org.
Jazyk:	angličtina
Zdroj:	Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Jul 25; Vol. 82 (4), pp. 336-349.
DOI:	10.1016/j.jacc.2023.05.024
Abstrakt:	Background: The relationship between omega-3 fatty acids and atrial fibrillation (AF) remains controversial. Objectives: This study aimed to determine the prospective associations of blood or adipose tissue levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with incident AF. Methods: We used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Each participating study conducted a de novo analyses using a prespecified analytical plan with harmonized definitions for exposures, outcome, covariates, and subgroups. Associations were pooled using inverse-variance weighted meta-analysis. Results: Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up. In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05). HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively. Conclusions: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained. Competing Interests: Funding Support and Author Disclosures The Fatty Acid Research Institute retrospectively provided a small honorarium to a subset of the analysts who participated in this study, but it had no role in the design, analysis, manuscript writing, nor decision to submit for publication. Detailed funding information for the individual cohorts can be found in the Supplemental Appendix, specifically Supplemental Table 4. None of the funders/sponsors played any role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr O'Donoghue is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Amgen, Novartis, Janssen, and AstraZeneca; and has received consulting fees from Amgen, Novartis, Janssen, and AstraZeneca. Dr Albert has received consulting fees from Boston Scientific, Medtronic, Novartis, and Element Science. Dr Morrow is a member of the TIMI Study group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Amgen, Anthos Therapeutics, Arca Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, Daiichi-Sankyo, Eisai, Intarcia, Janssen, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron, Roche, Siemens, The Medicines Company, and Zora Biosciences; and has received consulting fees from ARCA, InCarda, Inflammatix, Merck, Novartis, and Roche Diagnostics. Dr O’Keefe has a major ownership interest in Cardiotabs (a company that markets supplements including omega-3). Dr Mozaffarian, outside of the submitted work, has received research funding from the Gates Foundation, The Rockefeller Foundation, and the Vail Institute for Global Research; has received personal fees from Acasti Pharma, Barilla, Danone, and Motif FoodWorks; has served on the scientific advisory board of Beren Therapeutics, Brightseed, Calibrate, DayTwo (ended June 20, 2023), Elysium Health, Filtricine, Foodome, HumanCo, January Inc, Perfect Day, Season, and Tiny Organics; has stock ownership in Calibrate and HumanCo; and has chapter royalties from UpToDate. Dr Harris holds stock in OmegaQuant Analytics, LLC (a laboratory that offers blood fatty acid testing); and is on the Scientific Advisory Boards for the Schiff Institute Science and Innovation, Synspira, and the Seafood Nutrition Partnership. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu